Tilray Issues 1.61M Shares to Acquire Lyphe, Retires $6M Debt
TLRY•Tilray issued 398,666 shares April 15 for its Lyphe Group acquisition and 1.21 million shares June 3 to retire $6 million of 5.2% convertible notes. Lyphe’s platform has treated over 16,000 patients and dispensed 150,000 medical cannabis units, and the deal is expected to boost earnings next year.
1. Equity Issuance and Debt Swap
On April 15 Tilray issued 398,666 shares as part of its acquisition of UK-based Lyphe Group, and on June 3 it issued 1.21 million shares in a private debt-for-equity exchange, retiring $6 million of 5.2% convertible senior notes due 2027 without using cash.
2. Lyphe Acquisition Platform
The acquisition provides Tilray with a fully integrated medical cannabis ecosystem combining pharma-grade cultivation, clinical care, dispensing services and a digital pharmacy platform; Lyphe has treated over 16,000 patients and dispensed 150,000 units in the UK to date.
3. Earnings Outlook
Tilray expects the Lyphe deal to boost its earnings next year by expanding its international medical cannabis footprint and leveraging the integrated platform for enhanced revenue growth.
4. Market Reaction
Shares climbed 3% on the issuance and debt retirement news, marking the stock's best day in over two weeks as investor sentiment improved.
